NWBO
NORTHWEST BIOTHERAPEUTICS INC
-0.00 (-1.82%)0.17USD577K成交股數285M市值–本益比(近四季)131.0股價營收比+516.0%營收年增(近四季)2026-11-12下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 807K+516% | 494K+32% | 672K+88% | 200K-61% | 131K-54% | 375K-16% | 357K-12% | 510K+154% | 284K | 445K | 406K | 201K |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 5.7M | 4.9M | 5.6M | 7.5M | 7.4M | 8.4M | 8.1M | 8.3M | 7.9M | 7.5M | 7.2M | 6.2M |
| 銷售管理費用 | 6.7M | 6.5M | 8.6M | 7.1M | 7.5M | 9.3M | 7.0M | 9.7M | 8.1M | 8.1M | 7.0M | 7.6M |
| 營業利益 | −11.6M-21% | −10.9M-37% | −13.5M-9% | −14.3M-18% | −14.8M-6% | −17.3M+14% | −14.8M+7% | −17.5M+29% | −15.7M | −15.1M | −13.8M | −13.6M |
| 營業利益率 | -1,438.0% | -2,206.5% | -2,009.5% | -7,160.0% | -11,281.7% | -4,616.3% | -4,145.9% | -3,424.3% | -5,543.7% | -3,402.7% | -3,405.2% | -6,754.7% |
| 稅後淨利 | −9.2M-40% | −3.1M-84% | 1.4M-107% | −26.8M+50% | −15.4M-16% | −19.3M+38% | −19.4M-18% | −17.9M+24% | −18.3M | −14.0M | −23.5M | −14.4M |
| 淨利率 | -1,142.6% | -621.3% | 206.5% | -13,414.5% | -11,738.9% | -5,158.1% | -5,426.9% | -3,503.7% | -6,447.9% | -3,140.9% | -5,793.6% | -7,188.1% |
| 稀釋 EPS | -0.010% | 0.00-100% | 0.00-100% | -0.020% | -0.01-50% | -0.01-50% | -0.020% | -0.02+100% | -0.02 | -0.02 | -0.02 | -0.01 |
| 稀釋股數 | 1.64B | 1.58B | 1.46B | 1.5M | 1.44B | 1.36B | 1.3M | 1.2M | 1.2M | 1.1M | 1.1M | 1.1M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 595K | 1.8M | 3.0M | 4.6M | 4.3M | 2.8M | 2.9M | 2.9M | 2.5M | 2.1M | 6.1M | 1.4M |
| 應收帳款 | – | – | – | – | – | – | – | – | – | – | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 75.9M | 80.1M | 81.3M | 30.6M | 29.5M | 27.5M | 29.3M | 28.2M | 28.6M | 27.9M | 31.5M | 28.4M |
| 有息負債 | 52.0M | 59.4M | 60.0M | 72.2M | 64.7M | 64.1M | 53.3M | 51.0M | 44.4M | 40.8M | 32.9M | 26.0M |
| 總負債 | 111M | 118M | 129M | 126M | 116M | 112M | 93.6M | 86.0M | 82.0M | 74.9M | 68.9M | 64.1M |
| 股東權益 | −45.2M | −50.5M | −60.3M | −109M | −100M | −99.5M | −80.1M | −76.5M | −73.3M | −65.8M | −70.1M | −61.0M |
| 負債比 | 145.8% | 147.5% | 158.5% | 411.2% | 393.2% | 408.4% | 319.1% | 304.6% | 287.2% | 268.9% | 218.9% | 225.4% |
| 淨現金(現金 − 有息負債) | −51.4M | −57.6M | −57.0M | −67.6M | −60.4M | −61.4M | −50.3M | −48.2M | −42.0M | −38.7M | −26.8M | −24.6M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −12.5M+33% | – | – | – | −9.4M | – | – | −12.4M | – | – | – |
| 資本支出 | – | 129K | – | – | – | 93K | – | – | 239K | – | – | – |
| 自由現金流 | – | −12.6M+33% | – | – | – | −9.5M | – | – | −12.6M | – | – | – |
| 折舊攤銷 | – | 771K | – | – | – | 400K | – | – | 400K | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -2,558.3% | – | – | – | -2,536.3% | – | – | -4,452.5% | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 1.4M | -0.3% | −60.2M | -4,365.9% | -0.04 | −46.3M |
| FY2024 | 1.4M | -28.5% | −83.8M | -6,062.1% | -0.07 | −58.0M |
| FY2023 | 1.9M | +14.8% | −62.6M | -3,240.1% | -0.06 | – |
| FY2022 | 1.7M | +67.5% | −105M | -6,240.8% | -0.10 | – |
| FY2021 | 1.0M | -22.2% | 179M | 17,823.5% | -0.06 | – |
| FY2020 | 1.3M | -46.4% | −530M | -41,039.6% | -0.73 | – |
| FY2019 | 2.4M | +485.0% | −20.8M | -863.6% | -0.04 | −32.0M |
| FY2018 | 412K | – | −35.8M | -8,687.9% | -0.12 | – |